



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	SCHNEIDER MARK M ET AL: "Paradoxical attenuation of fibrinolysis by reversible inhibitors of TAFIa" BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), page 254a, XP009054859 &43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001 ISSN: 0006-4971	31-38	C12Q1/00 G01N33/53 G01N33/573 G01N33/86 C12Q1/56 C12Q1/37 G01N33/68 G01N33/574
A	* the whole document *	1-30	
A	SCHATTEMAN K A ET AL: "Assay of procarboxypeptidase U, a novel determinant of fibrinolytic cascade, in human plasma" CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY. WINSTON, US, vol. 45, no. 6, June 1999 (1999-06), pages 807-813, XP002196536 ISSN: 0009-9147 * page 809, column 2, paragraph 3 *	1-48	
A	BOUMA B N ET AL: "FACTOR XI DEPENDENT AND INDEPENDENT ACTIVATION OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) IN PLASMA ASSOCIATED WITH CLOT FORMATION" THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 82, no. 6, December 1999 (1999-12), pages 1703-1708, XP009044077 ISSN: 0340-6245 * page 1704, column 2, paragraph 1 *	1-48	
			TECHNICAL FIELDS SEARCHED (IPC)
			G01N C12Q
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 22 March 2006	Examiner Pellegrini, P
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	ANTOVIC J ET AL: "Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A." HAEMOPHILIA : THE OFFICIAL JOURNAL OF THE WORLD FEDERATION OF HEMOPHILIA. NOV 2001, vol. 7, no. 6, November 2001 (2001-11), pages 557-560, XP009054828 ISSN: 1351-8216 * the whole document * -----	18,39, 41,42,44	
			TECHNICAL FIELDS SEARCHED (IPC)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 22 March 2006	Examiner Pellegrini, P
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

专利名称(译)	凝血酶激活的纤维蛋白溶解抑制剂 (TAFI) 的诊断分析		
公开(公告)号	EP1539991A4	公开(公告)日	2006-05-17
申请号	EP2003791928	申请日	2003-08-29
[标]申请(专利权)人(译)	AMERICAN DIAGNOSTICA		
申请(专利权)人(译)	AMERICAN DIAGNOSTICA INC.		
当前申请(专利权)人(译)	AMERICAN DIAGNOSTICA INC.		
[标]发明人	GREENFIELD ROBERT S AN SEONG SOO A		
发明人	GREENFIELD, ROBERT, S. AN, SEONG, SOO, A.		
IPC分类号	C12Q1/00 C12Q1/37 C12Q1/56 G01N33/53 G01N33/573 G01N33/574 G01N33/68 G01N33/86		
CPC分类号	C12Q1/37 C12Q1/56 G01N33/57415 G01N33/57426 G01N33/6893 G01N33/86 G01N2333/81 G01N2800/085 G01N2800/224 G01N2800/226 G01N2800/32		
优先权	60/406756 2002-08-29 US		
其他公开文献	EP1539991A2 EP1539991B1		
外部链接	Espacenet		

摘要(译)

本发明涉及用于选择性测量35kD形式的凝血酶可激活的纤维蛋白溶解抑制剂 (TAFIa或TAFIai) 或其衍生物或变体, 但不是TAFI酶原 (TAFI) 或N末端激活肽的水平的诊断测定法。 TAFI。

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	SCHNEIDER MARK M ET AL: "Paradoxical attenuation of fibrinolysis by reversible inhibitors of TAFIa" BLOOD vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), page 254a, XP009054059 643RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1: ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001 ISSN: 0006-4971 * the whole document *	31-38	C12Q1/00 G01N33/53 G01N33/573 G01N33/86 C12Q1/56 C12Q1/37 G01N33/68 G01N33/574
A	* the whole document *	1-30	
A	SCHATTENMAN K A ET AL: "Assay of procarboxypeptidase U, a novel determinant of fibrinolytic cascade, in human plasma" CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WINSTON, US, vol. 45, no. 6, June 1999 (1999-06), pages 807-813, XP002196536 ISSN: 0009-9147 * page 809, column 2, paragraph 3 *	1-48	
A	BOUMA B N ET AL: "FACTOR XI DEPENDENT AND INDEPENDENT ACTIVATION OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) IN PLASMA ASSOCIATED WITH CLOT FORMATION, THROMBOSIS AND HEMOSTASIS, STUTTGART, DE, vol. 82, no. 6, December 1999 (1999-12), pages 1703-1708, XP009044077 ISSN: 0348-6245 * page 1704, column 2, paragraph 1 * ----- -/-	1-48	TECHNICAL FIELDS SEARCHED (IPC) G01N C12Q
The supplementary search report has been based on the last set of claims valid and available at the start of the search			
Place of search Munich		Date of completion of the search 22 March 2006	
Examiner Munich		Reviewer Pellegri, P	
CATEGORY OF CITED DOCUMENTS			
X: particularly relevant if taken alone Y: particularly relevant if considered with another document of the same category A: non-patent literature P: prior art document D: intermediate document			
1: entry is appropriate concerning the invention 2: earlier patent document, but published on, or after the filing date 3: document cited in the specification 4: document cited for other reasons 5: (number of the same patent family, corresponding document)			